Ray Dalio's DXCM Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 120,495 shares of DexCom, Inc. (DXCM) worth $8.11 M, representing 0.03% of the portfolio. First purchased in 2020-Q3, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in DXCM, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2021, adding 275,520 shares. Largest reduction occurred in Q4 2024, reducing 221,691 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's DexCom (DXCM) Holding Value Over Time
Track share changes against reported price movement
Quarterly DexCom (DXCM) Trades by Ray Dalio
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2020 | +69,676 | New Buy | 69,676 | $103.06 |
| Q4 2020 | +60,420 | Add 86.72% | 130,096 | $92.43 |
| Q1 2021 | +16,032 | Add 12.32% | 146,128 | $89.85 |
| Q2 2021 | +275,520 | Add 188.55% | 421,648 | $106.75 |
| Q3 2021 | -44,636 | Reduce 10.59% | 377,012 | $136.71 |
| Q4 2021 | +49,124 | Add 13.03% | 426,136 | $134.24 |
| Q1 2022 | +154,828 | Add 36.33% | 580,964 | $127.90 |
| Q2 2022 | +52,090 | Add 8.97% | 633,054 | $74.53 |
| Q3 2022 | -9,771 | Reduce 1.54% | 623,283 | $80.54 |
| Q4 2022 | -191,759 | Reduce 30.77% | 431,524 | $113.24 |
| Q1 2023 | +23,847 | Add 5.53% | 455,371 | $116.18 |
| Q2 2023 | -37,149 | Reduce 8.16% | 418,222 | $128.51 |
| Q3 2023 | +183,141 | Add 43.79% | 601,363 | $93.30 |
| Q4 2023 | -168,208 | Reduce 27.97% | 433,155 | $124.09 |
| Q1 2024 | -62,291 | Reduce 14.38% | 370,864 | $138.70 |
| Q2 2024 | -23,540 | Reduce 6.35% | 347,324 | $113.38 |
| Q3 2024 | -27,695 | Reduce 7.97% | 319,629 | $67.04 |
| Q4 2024 | -221,691 | Reduce 69.36% | 97,938 | $77.77 |
| Q1 2025 | -26,642 | Reduce 27.20% | 71,296 | $68.29 |
| Q2 2025 | +182,515 | Add 256.00% | 253,811 | $87.29 |
| Q3 2025 | -133,316 | Reduce 52.53% | 120,495 | $67.29 |
Ray Dalio's DexCom Investment FAQs
Ray Dalio first purchased DexCom, Inc. (DXCM) in Q3 2020, acquiring 69,676 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held DexCom, Inc. (DXCM) for 21 quarters since Q3 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's largest addition to DexCom, Inc. (DXCM) was in Q2 2021, adding 421,648 shares worth $45.01 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 120,495 shares of DexCom, Inc. (DXCM), valued at approximately $8.11 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, DexCom, Inc. (DXCM) represents approximately 0.03% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's peak holding in DexCom, Inc. (DXCM) was 633,054 shares, as reported at the end of Q2 2022. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.